bluebird jumps 72% on interim LentiGlobin data

bluebird bio Inc. (NASDAQ:BLUE) gained $35.39 (72%) to $84.28 on Tuesday, giving it a market cap of $2.4 billion, after it presented interim data from two Phase I/II trials of its LentiGlobin BB305 gene therapy at the American Society of Hematology (ASH) meeting in San Francisco.

The company said two patients with beta thalassemia major who received LentiGlobin BB305 in the Northstar (HGB-204) study have been free from the need for tranfusions for five and three months, respectively. bluebird said it was too early to draw conclusions about three other patients in the study, which includes patients with the beta-0/beta-0 genotype of beta thalassemia major. ...